Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Brain tumor, adult: Ependymoma/Ependymal tumors
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 30 for your search:
Start Over
Trastuzumab in Treating Leptomeningeal Metastases in Patients with HER2-Positive Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 10C03, NCI-2011-00110, STU00040150, NCT01325207
Carboxyamidotriazole Orotate with or without Bevacizumab in Treating Patients with Recurrent Malignant Glioma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: Pro00044274, NCI-2014-00031, NCT01954030
Carboxyamidotriazole Orotate with or without Lomustine in Treating Patients with Recurrent Malignant Glioma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: Pro00047969, NCI-2014-00304, NCT01989052
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 70
Trial IDs: NLG2102, NCI-2014-02063, NCT02052648
Combination Chemotherapy With or Without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Patients With Malignant Brain Tumors
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 to 75
Trial IDs: ONC-02019-L, NCI-2013-00781, eIRB #922, OHSU-7328, OHSU-922, OHSU-ONC-02059-L, CASE-CCF-6385, NCT00075387
Bendamustine Hydrochloride in Treating Patients with Recurrent or Progressive Anaplastic Glioma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 6803, NCI-2010-00714, UWCC-6803, FHCRC-6803, IR-6803, NCCN-C01, NCT00823797
Poly ICLC in Treating Younger Patients With Recurrent or Progressive Low Grade Gliomas
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 0 to 21
Trial IDs: Poly-ICLC, NCI-2013-02084, NCT01188096
Carboplatin and Bevacizumab in Treating Patients with Recurrent Ependymoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CERN09-02, NCI-2011-01283, NCT01295944
Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas and Favorable Grade 3 Gliomas
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-439, NCI-2011-00915, NCT01358058
Aminolevulinic Acid Hydrochloride in Visualizing Tumors in Patients with Newly Diagnosed or Recurrent Malignant Gliomas Undergoing Surgery
Phase: Phase II
Type: Diagnostic, Treatment
Age: 18 and over
Trial IDs: WCI1999-11, NCI-2011-03426, IRB00051663, NCT01445691
Hypofractionated Radiation Therapy in Combination with Temozolomide and Bevacizumab in Treating Patients with Recurrent High-Grade Glioblastoma Multiforme or Anaplastic Glioma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: NU 11C02, NCI-2011-02904, NCI CTRP#, STU00053636, NCT01478321
Donor Bone Marrow Transplant in Treating Patients with High-Risk Solid Tumors
Phase: Phase II
Type: Treatment
Age: 0 to 40
Trial IDs: J12106, NCI-2013-00702, CIR00008429, CIR00009228, NA_00076243, NA_00076243 / CIR00009228, NCT01804634
Surgery and Second-Course Radiation Therapy in Treating Younger Patients With Recurrent Ependymoma
Phase: Phase II
Type: Treatment
Age: 1 to 21
Trial IDs: RERTEP, NCI-2014-00906, NCT02125786
Dexanabinol in Treating Patients With Recurrent Brain Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: SK01-ETS2101, NCI-2012-01204, 111827, NCT01654497
Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: HCI57337, NCI-2015-00245, NCT01672463
Mebendazole and Temozolomide in Treating Patients With Newly Diagnosed High-Grade Gliomas
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: J1194, NCI-2013-00047, NCT01729260
Viral Therapy before and during Surgery and Flucytosine after Surgery in Treating Patients with Recurrent High-Grade Glioma
Phase: Phase I
Type: Treatment
Age: 18 to 80
Trial IDs: Tg 511-13-01, NCI-2014-02478, TOG1314, NCT01985256
A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: ATI001-102, NCI-2014-00752, NCT02026271
Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AG120-C-002, NCI-2014-00868, NCT02073994
Temozolomide and Ascorbic Acid in Treating Patients with Recurrent High-Grade Glioma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 735-13, NCI-2014-01061, NCT02168270
Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients with Recurrent High Grade Gliomas
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 13P.528, NCI-2014-01344, 2013-12, 3007, NCT02186509
Genetically Modified T-cells in Treating Patients with Recurrent or Refractory Malignant Glioma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: 13384, NCI-2014-01488, 117388, NCT02208362
D2C7-IT via Convection-Enhanced Delivery in Treating Patients with Recurrent Malignant Glioma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: Pro00053325, NCI-2015-00297, NCT02303678
Pembrolizumab with Hypofractionated Stereotactic Irradiation and Bevacizumab in Treating Patients with Recurrent High-Grade Gliomas
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MCC-17978, NCI-2015-00751, 14.12.0008, Merck IISP 51561, NCT02313272
Safety, Tolerability & PK of KX2-361 in Subjects w Adv. Malignancies Refractory to Conventional Therapies
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: KX02-01-13, NCI-2015-00135, NCT02326441
Start Over